Informations générales (source: ClinicalTrials.gov)
3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension (HTP3S)
Observational
Centre Hospitalier Universitaire de Nice (Voir sur ClinicalTrials)
octobre 2014
juin 2019
29 juin 2024
Pulmonary hypertension is a rare and severe disease, affecting a young population.
Survival is very poor and has been closely related to right ventricular dysfunction.
Current prognostic equations rely mostly on right heart catheterization data. The
identification of simple echocardiographic prognostic factor is urgently needed. It could
help identifying with a non invasive method, high risk patients who could benefit from an
intensive specific therapy. 3D right ventricular imaging is a new echocardiographic tool
which provides RV volumic analysis, RV ejection fraction, overcoming the classical limits
of 2D ultrasound.
The aim of this study is to validate a new software for 3D analysis of the right
ventricle and assess its prognostic role in pulmonary hypertension.
To do so, the investigators will realize a prospective monocentric longitudinal cohort
study, including 100 pulmonary hypertension patients. Echocardiographic data will be
collected at baseline and after 6 months.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hopital Pasteur - Chu Nice - 06000 - Nice - France | PAMELA MOCERI, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patients > 18 years old
- Pulmonary hypertension diagnosed by right heart catheterization
- Informed consent obtained
- Affiliation to the French national health insurance
- Patients > 18 years old
- Pulmonary hypertension diagnosed by right heart catheterization
- Informed consent obtained
- Affiliation to the French national health insurance
- Associated significant left heart disease
- Sub-optimal acoustic windows
- Patient unable to attend follow-up visits